| Message Author: | IRWIN JAMES FRANKEL |
| Subject: | Exelixis, Inc. (EXEL) |
| Message: |
Exelixis Expands the Cabozantinib Development Program Through NCI-CTEP Collabo |
| Report Type: | |
| Note: Reports of new account spamming will often be addressed more quickly if reported here. |
Additional Comments (No need to state the obvious!) | |
| You must first login to submit a TOU Violation! |